Isis announces Phase 2 antisense data in FCS

Isis Pharmaceuticals (ISIS) outlines data from a Phase 2 trial of the antisense drug ISIS-APOCIIIRx in familial chylomicronemia syndrome.

All three patients saw "substantial reductions" (average was 69%) in triglyceride levels.

The disease only affects 3-5K patients worldwide, so the trial was quite small, but the data "are ... compelling and demonstrate the potential of ISIS-APOCIIIRx to produce dramatic triglyceride lowering in patients with FCS," Dr. Daniel Gaudet notes.

The company says "the significant unmet medical need [associated with FCS] should enable [ISIS to] rapidly move forward." (PR)

From other sites
Comments (2)
  • arthurs1
    , contributor
    Comments (396) | Send Message
    The ISIS train keps a rolling all night long.....even on weekends.
    21 Sep 2013, 04:40 PM Reply Like
  • brown25
    , contributor
    Comments (70) | Send Message
    I would like to take this opportunity to thank the "Tedster", Barons, and Con-Fusuion research to allow me to purchase more ISIS on the cheap last month!!!
    21 Sep 2013, 05:18 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs